Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines-Reference-Cited by-同舟云学术

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

Published:2021-11-02 Issue: Volume: Page:1-10
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Du Qian-qian¹,Shi Wei¹,Yu Dan¹,Yao Kai-hu¹^ORCID

Affiliation:

1. Key Laboratory of Major Diseases in Children, Ministry of Education, National Key Discipline of Pediatrics, Laboratory of Microbiology, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

Funder

no funding associated

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1985353

Reference99 articles.

1. Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

2. Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis

3. Changes in Capsule and Drug Resistance of Pneumococci after Introduction of PCV7, Japan, 2010–2013

4. Increase in incidence of invasive pneumococcal disease caused by serotype 3 in children eight years after the introduction of the pneumococcal conjugate vaccine in Hong Kong

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the pathogenesis and treatment of pneumococcal meningitis;Virulence;2024-08-27

2. Vaccines for the Elderly and Vaccination Programs in Europe and the United States;Vaccines;2024-05-22

3. Intranasal bivalent vaccine with recombinant Influenza Virus expressing Pneumococcal Surface Protein A (PspA) protects against Streptococcus pneumoniae and Influenza A virus infection in mice;2024-04-02

4. Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial;Vaccine;2024-04

5. Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older;Vaccine;2024-04